CELL INTELLIGENCE · 肿瘤细胞治疗研究

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

一种新型三基因敲除同种异体 BCMA CAR-T 细胞疗法（CT0590）用于多发性骨髓瘤：临床前及 1 期研究

A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study.

我如何治疗浆细胞白血病

How I treat plasma cell leukemia.

靶向 BCMA 和 GPRC5D 的双特异性抗体治疗浆细胞白血病的真实世界结局

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

B 细胞成熟抗原在急性髓系白血病中的有限表达

Limited expression of B-cell maturation antigen in acute myeloid leukemia.

原发性浆细胞白血病

Primary Plasma Cell Leukemia.

整合跨膜 CD28 结构域后学术性 CAR-T ARI0002h 对正常和低表达 BCMA 骨髓瘤细胞增强的抗肿瘤活性

Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane

将 CD28-TMD 整合到 ARI0002h CAR 中可增强肿瘤控制，即使在靶抗原下调的复发模型中也是如此，从而提供更好的长期疾病管理。该修饰增强了对 BCMA 表达正常和降低的 MM 肿瘤细胞系的效力，表现出更优的代谢耐力和体内活性。

糖皮质激素改善 CAR-T 细胞诱导的细胞因子释放综合征而不抑制多发性骨髓瘤治疗

Corticosteroids ameliorate CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment.

我们的结果应鼓励进一步开展临床研究，以设计既能优化 CAR-T 细胞毒性治疗、又能维持抗肿瘤活性的糖皮质激素方案。

全人源抗 GPRC5D CAR-T 细胞疗法 RD118 在复发/难治性多发性骨髓瘤中诱导持久缓解

The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma.

基于 BAFF 的三功能 T 细胞衔接器触发针对 B 细胞恶性肿瘤的强效抗肿瘤免疫

BAFF-based trifunctional T-cell engagers trigger robust tumor immunity against B-cell malignancies.